NCT03866525: OH2 Oncolytic Viral Therapy in Solid Tumors

NCT03866525
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with central nervous system (CNS) metastases with clinical symptoms
https://ClinicalTrials.gov/show/NCT03866525

Comments are closed.

Up ↑